title: [Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
abstract: 140 patients with myocardial infarction in combination with non-alcoholic steatohepatitis, 58 patients took medium theraupeutic doses of rosuvastatin of 10 mg/day and 82 patients--torvastatin of 40 mg/day, have been examined. The study found significant progression of dyslipidemia, when the statins (improving blood total cholesterol and TG by 34% and LDL cholesterol by 38%). In patients who continued receiving statins, noted the positive dynamics of lipidohramy: in patients receiving rosuvastatin 10 mg levels of total cholesterol and LDL cholesterol decreased by 36% and 43%, respectively, with atorvastatin 40 mg level indicators fell by 34% and 40% respectively. Therapy rosuvastatin 10 mg had an advantage over the use of atorvastatin 40 mg in raising HDL cholesterol by 21%, and reduction of TG level by 37%. It is proved that the method furthers statins improves disease in patients with acute myocardial infarction, prevents the development of coronary artery disease resistant and recurrent acute coronary events, reduces the incidence of hospitalizations for heart failure progression.
authors.forename: I M
authors.initials: IM
authors.lastname: Skrypnyk
authors.forename: T V
authors.initials: TV
authors.lastname: Dubrovins'ka
mesh_terms: D000069059:Atorvastatin; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D012008:Recurrence; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin